MEDTE:PA:PA-BNP Paribas Easy ECPI Global ESG Med Tech UCITS ETF EUR Capitalisation (EUR)

ETF | Others |

Last Closing

USD 9.1417

Change

+0.05 (+0.51)%

Market Cap

N/A

Volume

16.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

+0.61 (+1.30%)

USD 55.36B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

+0.80 (+0.14%)

USD 14.29B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+0.07 (+0.02%)

USD 13.82B
WRD:PA HSBC MSCI World UCITS ETF

+0.10 (+0.26%)

USD 11.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

+2.87 (+1.10%)

USD 9.11B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+0.10 (+0.02%)

USD 8.85B
WLD:PA Lyxor UCITS MSCI World D-EUR

+1.10 (+0.31%)

USD 7.99B
HHH:PA HSBC S&P 500 UCITS ETF

+0.07 (+0.12%)

USD 7.71B
LCWD:PA Multi Units Luxembourg - Lyxor..

N/A

USD 6.91B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

-0.16 (-2.18%)

USD 5.25B

ETFs Containing MEDTE:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.82% 69% C- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.82% 69% C- 63% D
Trailing 12 Months  
Capital Gain 4.06% 24% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.06% 21% F 44% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.65% 26% F 41% F
Dividend Return 2.65% 26% F 40% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 4.31% 89% A- 94% A
Risk Adjusted Return 61.30% 40% F 67% D+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.